Moderate and large effect sizes of differences in symptom severity means of patients with CML treated with different TKIs
| . | Drug 1, mean (SD) . | Drug 2, mean (SD) . | Difference . | Effect size . |
|---|---|---|---|---|
| Imatinib (drug 1) vs nilotinib (drug 2) | ||||
| Nausea | 1.03 (1.64) | 0.41 (1.10) | 0.62 | 0.40 |
| Dry mouth | 1.94 (2.31) | 1.14 (2.10) | 0.81 | 0.36 |
| Numbness and tingling | 1.49 (2.01) | 0.91 (1.54) | 0.58 | 0.31 |
| Diarrhea | 1.68 (2.37) | 0.55 (1.37) | 1.13 | 0.52 |
| Swelling | 2.17 (2.08) | 1.18 (1.71) | 0.99 | 0.49 |
| Muscle soreness | 2.55 (2.54) | 1.59 (2.30) | 0.96 | 0.39 |
| Mean CML-module items | 1.75 (1.45) | 1.20 (1.46) | 0.55 | 0.38 |
| Mean 5 most severe symptoms | 2.39 (2.05) | 1.73 (1.84) | 0.66 | 0.33 |
| Imatinib (drug 1) vs dasatinib (drug 2) | ||||
| Nausea | 1.03 (1.64) | 0.44 (1.52) | 0.59 | 0.37 |
| Distress | 1.73 (2.31) | 1.03 (1.59) | 0.70 | 0.33 |
| Lack of appetite | 0.73 (1.52) | 0.18 (0.52) | 0.56 | 0.43 |
| Dry mouth | 1.94 (2.31) | 1.26 (1.91) | 0.68 | 0.31 |
| Feeling drowsy | 2.44 (2.42) | 1.53 (1.66) | 0.91 | 0.41 |
| Muscle soreness | 2.55 (2.54) | 1.68 (2.31) | 0.87 | 0.35 |
| Mean all symptom items | 1.66 (1.41) | 1.42 (1.96) | 0.48 | 0.38 |
| Mean CML-module Items | 1.75 (1.45) | 1.08 (1.01) | 0.66 | 0.50 |
| Dasatinib (drug 1) vs nilotinib (drug 2) | ||||
| Distress | 1.03 (1.59) | 1.86 (2.23) | 0.83 | 0.45 |
| Vomiting | 0.09 (0.29) | 0.50 (1.41) | 0.41 | 0.45 |
| Headache | 0.56 (0.93) | 1.19 (1.78) | 0.63 | 0.48 |
| . | Drug 1, mean (SD) . | Drug 2, mean (SD) . | Difference . | Effect size . |
|---|---|---|---|---|
| Imatinib (drug 1) vs nilotinib (drug 2) | ||||
| Nausea | 1.03 (1.64) | 0.41 (1.10) | 0.62 | 0.40 |
| Dry mouth | 1.94 (2.31) | 1.14 (2.10) | 0.81 | 0.36 |
| Numbness and tingling | 1.49 (2.01) | 0.91 (1.54) | 0.58 | 0.31 |
| Diarrhea | 1.68 (2.37) | 0.55 (1.37) | 1.13 | 0.52 |
| Swelling | 2.17 (2.08) | 1.18 (1.71) | 0.99 | 0.49 |
| Muscle soreness | 2.55 (2.54) | 1.59 (2.30) | 0.96 | 0.39 |
| Mean CML-module items | 1.75 (1.45) | 1.20 (1.46) | 0.55 | 0.38 |
| Mean 5 most severe symptoms | 2.39 (2.05) | 1.73 (1.84) | 0.66 | 0.33 |
| Imatinib (drug 1) vs dasatinib (drug 2) | ||||
| Nausea | 1.03 (1.64) | 0.44 (1.52) | 0.59 | 0.37 |
| Distress | 1.73 (2.31) | 1.03 (1.59) | 0.70 | 0.33 |
| Lack of appetite | 0.73 (1.52) | 0.18 (0.52) | 0.56 | 0.43 |
| Dry mouth | 1.94 (2.31) | 1.26 (1.91) | 0.68 | 0.31 |
| Feeling drowsy | 2.44 (2.42) | 1.53 (1.66) | 0.91 | 0.41 |
| Muscle soreness | 2.55 (2.54) | 1.68 (2.31) | 0.87 | 0.35 |
| Mean all symptom items | 1.66 (1.41) | 1.42 (1.96) | 0.48 | 0.38 |
| Mean CML-module Items | 1.75 (1.45) | 1.08 (1.01) | 0.66 | 0.50 |
| Dasatinib (drug 1) vs nilotinib (drug 2) | ||||
| Distress | 1.03 (1.59) | 1.86 (2.23) | 0.83 | 0.45 |
| Vomiting | 0.09 (0.29) | 0.50 (1.41) | 0.41 | 0.45 |
| Headache | 0.56 (0.93) | 1.19 (1.78) | 0.63 | 0.48 |